Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo

被引:8
作者
Bymaster, FP [1 ]
Carter, PA [1 ]
DeLapp, NW [1 ]
Calligaro, DO [1 ]
Felder, CC [1 ]
机构
[1] Lilly Corp Ctr, Neurosci Res Div, Indianapolis, IN 46285 USA
关键词
muscarinic M-1 receptor; phosphoinositide hydrolysis; receptor reserve; muscarinic agonist; pilocarpine;
D O I
10.1016/S0006-8993(01)02889-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The ability of the partial muscarinic agonist pilocarpine to increase in vivo phosphoinositide. (PI) hydrolysis in mouse brain was compared to two full agonists. Pilocarpine increased in vivo phosphoinositide (PI) hydrolysis in cortex, striatum, and to the greatest extent in the hippocampus. Pilocarpine injected either subcutaneously or intracerebroventricularly robustly increased in vivo PI hydrolysis in hippocampus up to 500% of control levels and the increases were blocked by the muscarinic antagonist scopolamine. The increases in vivo PI hydrolysis induced by pilocarpine, were 60-75% of the magnitude of the full muscarinic agonists oxotremorine-M and cis-dioxolane. The muscarinic. M-1 preferring antagonist pirenzepine potently blocked pilocarpine-induced increases in in vivo PI hydrolysis, consistent with the increase being mediated by M-1 receptors. Since pilocarpine is a relatively weak partial agonist, these data suggest a substantial level of receptor reserve for the PI response in mouse hippocampus. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:165 / 171
页数:7
相关论文
共 35 条
[1]   THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[2]   Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].
Bodick, NC ;
Offen, WW ;
Levey, AI ;
Cutler, NR ;
Gauthier, SG ;
Satlin, A ;
Shannon, HE ;
Tollefson, GD ;
Rasmussen, K ;
Bymaster, FP ;
Hurley, DJ ;
Potter, WZ ;
Paul, SM .
ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473
[3]  
BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
[4]  
Bymaster FP, 1997, DRUG DEVELOP RES, V40, P158, DOI 10.1002/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.3.CO
[5]  
2-6
[6]  
BYMASTER FP, 1993, J PHARMACOL EXP THER, V267, P16
[7]   Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects [J].
Bymaster, FP ;
Carter, PA ;
Peters, SC ;
Zhang, W ;
Ward, JS ;
Mitch, CH ;
Calligaro, DO ;
Whitesitt, CA ;
DeLapp, N ;
Shannon, HE ;
Rimvall, K ;
Jeppesen, L ;
Sheardown, MJ ;
Fink-Jensen, A ;
Sauerberg, P .
BRAIN RESEARCH, 1998, 795 (1-2) :179-190
[8]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[9]  
CHENG YC, 1973, BIOCHEM PHARMACOL, V22, P3090
[10]   PHYSOSTIGMINE AND ARECOLINE - EFFECTS OF INTRAVENOUS INFUSIONS IN ALZHEIMER PRESENILE-DEMENTIA [J].
CHRISTIE, JE ;
SHERING, A ;
FERGUSON, J ;
GLEN, AIM .
BRITISH JOURNAL OF PSYCHIATRY, 1981, 138 (JAN) :46-50